Bicara Therapeutics (NASDAQ:BCAX) CEO Claire Mazumdar Sells 3,817 Shares of Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX) CEO Claire Mazumdar sold 3,817 shares of the company’s stock in a transaction that occurred on Friday, March 6th. The shares were sold at an average price of $18.75, for a total transaction of $71,568.75. Following the completion of the transaction, the chief executive officer owned 339,392 shares in the company, valued at approximately $6,363,600. This represents a 1.11% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Claire Mazumdar also recently made the following trade(s):

• On Wednesday, March 4th, Claire Mazumdar sold 2,631 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.73, for a total value of $49,278.63.
• On Thursday, March 5th, Claire Mazumdar sold 1,786 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.74, for a total transaction of $33,469.64.

Bicara Therapeutics Trading Down 0.2%

Bicara Therapeutics stock traded down $0.03 during mid-day trading on Friday, hitting $18.47. 471,766 shares of the company’s stock were exchanged, compared to its average volume of 541,313. The stock has a 50 day moving average of $16.47 and a two-hundred day moving average of $15.75. Bicara Therapeutics Inc. has a 1-year low of $7.80 and a 1-year high of $19.71. The stock has a market cap of $1.01 billion, a P/E ratio of -8.25 and a beta of -0.78.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. BTIG Research reissued a “buy” rating on shares of Bicara Therapeutics in a report on Thursday, January 15th. Wells Fargo & Company increased their target price on Bicara Therapeutics from $8.00 to $11.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 11th. Citigroup initiated coverage on shares of Bicara Therapeutics in a research report on Thursday, January 29th. They issued an “outperform” rating for the company. Citizens Jmp began coverage on shares of Bicara Therapeutics in a research note on Thursday, January 29th. They issued a “market perform” rating and a $31.00 target price on the stock. Finally, HC Wainwright restated a “buy” rating on shares of Bicara Therapeutics in a research report on Wednesday, January 14th. Seven investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $28.33.

Institutional Investors Weigh In On Bicara Therapeutics

Large investors have recently bought and sold shares of the company. Deutsche Bank AG increased its holdings in shares of Bicara Therapeutics by 0.9% during the fourth quarter. Deutsche Bank AG now owns 128,626 shares of the company’s stock worth $2,165,000 after buying an additional 1,171 shares in the last quarter. Legal & General Group Plc lifted its holdings in shares of Bicara Therapeutics by 64.1% in the 2nd quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock worth $29,000 after purchasing an additional 1,233 shares in the last quarter. Ameritas Investment Partners Inc. boosted its position in shares of Bicara Therapeutics by 73.0% during the second quarter. Ameritas Investment Partners Inc. now owns 3,493 shares of the company’s stock valued at $32,000 after buying an additional 1,474 shares during the last quarter. Mariner LLC grew its position in Bicara Therapeutics by 3.0% in the 4th quarter. Mariner LLC now owns 64,562 shares of the company’s stock worth $1,087,000 after purchasing an additional 1,902 shares in the last quarter. Finally, Invesco Ltd. increased its position in shares of Bicara Therapeutics by 13.2% during the second quarter. Invesco Ltd. now owns 16,877 shares of the company’s stock valued at $157,000 after acquiring an additional 1,962 shares during the last quarter.

More Bicara Therapeutics News

Here are the key news stories impacting Bicara Therapeutics this week:

• Positive Sentiment: Several institutional investors increased or initiated positions in BCAX recently (e.g., Woodline, Geode, Nan Fung, AQR), which supports demand from professional managers and can offset selling pressure. Read More.
• Positive Sentiment: Analyst coverage remains largely favorable — multiple firms maintain Buy/Outperform ratings and the consensus price target sits well above the current price, providing a bullish backdrop for longer‑term holders. Read More.
• Neutral Sentiment: The company announced an inducement equity grant under Nasdaq Rule 5635(c)(4) for a new hire — routine for growth‑stage biotech but can add modest dilution expectations. Read More.
• Neutral Sentiment: Published short‑interest entries for early March report “large increases” but show 0 shares/NaN changes — the data appears erroneous and does not provide reliable evidence of increased shorting. (No actionable short‑sale signal.)
• Negative Sentiment: CFO Ivan Hyep sold stock across March 3–4 (totaling 16,518 shares across recent sales), reducing his stake; sizable CFO sales can sap near‑term sentiment. Read More.
• Negative Sentiment: COO Ryan Cohlhepp sold 17,392 shares on March 3 (~7.8% reduction in his holding). Executive selling at this scale may be viewed as liquidity‑taking and can pressure the share price. Read More.
• Negative Sentiment: Insider David Raben sold ~16,500 shares in two transactions (including a 16,300‑share sale), representing a large reduction in one filing; founder/executive selling is commonly interpreted negatively by the market. Read More.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.